EBS - Emergent BioSolutions Triples Its Coronavirus-Vaccine Manufacturing Contract With AstraZeneca
Chalk up another contract to manufacture a coronavirus vaccine for Emergent BioSolutions (NYSE: EBS). This time from a repeat customer: AstraZeneca (NYSE: AZN).
Emergent BioSolutions, which is focused on bioterrorism and emergent diseases but also has a contract-manufacturing division, has previously partnered with Johnson & Johnson, Novavax, and Vaxart, as well as the aforementioned AstraZeneca, to help manufacture vaccines to prevent COVID-19.
The previous deal between Emergent and AstraZeneca, which was established in June, provided Emergent with $87 million in exchange for setting up the manufacturing process, and an initial reservation for raw materials and capacity to manufacture AZD1222, AstraZeneca's coronavirus vaccine, which it licensed from the University of Oxford and its spin-out company, Vaccitech.